You are here:
High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions
Citation:
Lynch, C., S. Sakamuru, M. Ooka, R. Huang, C. Klumpp-Thomas, P. Shinn, D. Gerhold, A. Rossoshek, S. Michael, W. Casey, M. Santillo, S. Fitzpatrick, R. Thomas, A. Simeonov, AND M. Xia. High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions. Annual Review of Pharmacology and Toxicology. Annual Reviews Inc., Palo Alto, CA, 64:191-209, (2024). https://doi.org/10.1146/annurev-pharmtox-112122-104310
Impact/Purpose:
N/A
Description:
Traditionally, chemical toxicity is determined by in vivo animal studies, which are low throughput, expensive, and sometimes fail to predict compound toxicity in humans. Due to the increasing number of chemicals in use and the high rate of drug candidate failure due to toxicity, it is imperative to develop in vitro, high-throughput screening methods to determine toxicity. The Tox21 program, a unique research consortium of federal public health agencies, was established to address and identify toxicity concerns in a high-throughput, concentration-responsive manner using a battery of in vitro assays. In this article, we review the advancements in high-throughput robotic screening methodology and informatics processes to enable the generation of toxicological data, and their impact on the field; further, we discuss the future of assessing environmental toxicity utilizing efficient and scalable methods that better represent the corresponding biological and toxicodynamic processes in humans.
URLs/Downloads:
DOI: High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions
https://pubmed.ncbi.nlm.nih.gov/37506331/